Condition

Anti-Retroviral Agents

ClinicalTrials.gov condition label

Clinical trials3

Recruiting0

Common interventions5

Lead sponsors shown3

Clinical trials

3 shown

Safety, PK, and PD Study of IVRs Releasing TFV and LNGNCT03279120 · 2017-09-28

Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological SuppressionNCT03251690 · 2016-10-27

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected PatientsNCT00412646 · 2002-06-01

Common interventions

PlaceboDRUG1 Tenofovir/Emtricitabine/EfavirenzDRUG1 Tenofovir/Emtricitabine/RilpivirineDRUG1 TFV/LNG IVRDRUG1 TMC125DRUG1

Leading sponsors

CONRAD1 Mahidol University1 Tibotec Pharmaceuticals, Ireland1

Trial status mix

COMPLETED3

Phase mix

NA1

PHASE11

PHASE21

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.